Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827
Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827
Wojciech Bartminski
European Outcomes Research, Health Outcomes Scientist, Oncology & Neuroscience, EMS AREA
Read
1404
Timeswas read the article
752
Total PDF
652
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 38 | 33 | 71 |
| 2025 5 | 48 | 51 | 99 |
| 2025 4 | 41 | 36 | 77 |
| 2025 3 | 37 | 34 | 71 |
| 2025 2 | 32 | 34 | 66 |
| 2025 1 | 20 | 31 | 51 |
| 2024 12 | 19 | 34 | 53 |
| 2024 11 | 36 | 51 | 87 |
| 2024 10 | 23 | 29 | 52 |
| 2024 9 | 28 | 28 | 56 |
| 2024 8 | 49 | 34 | 83 |
| 2024 7 | 25 | 25 | 50 |
| 2024 6 | 19 | 21 | 40 |
| 2024 5 | 21 | 37 | 58 |
| 2024 4 | 22 | 17 | 39 |
| 2024 3 | 20 | 14 | 34 |
| 2024 2 | 18 | 23 | 41 |
| 2024 1 | 17 | 28 | 45 |
| 2023 12 | 13 | 14 | 27 |
| 2023 11 | 22 | 29 | 51 |
| 2023 10 | 12 | 30 | 42 |
| 2023 9 | 15 | 28 | 43 |
| 2023 8 | 23 | 25 | 48 |
| 2023 7 | 18 | 27 | 45 |
| 2023 6 | 13 | 8 | 21 |
| 2023 5 | 18 | 24 | 42 |
| 2023 4 | 5 | 7 | 12 |
Show all
